WO2005123780A3 - Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis - Google Patents

Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis Download PDF

Info

Publication number
WO2005123780A3
WO2005123780A3 PCT/US2005/011996 US2005011996W WO2005123780A3 WO 2005123780 A3 WO2005123780 A3 WO 2005123780A3 US 2005011996 W US2005011996 W US 2005011996W WO 2005123780 A3 WO2005123780 A3 WO 2005123780A3
Authority
WO
WIPO (PCT)
Prior art keywords
serum half
mutagenesis
lives
alteration
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/011996
Other languages
French (fr)
Other versions
WO2005123780A2 (en
Inventor
Paul R Hinton
Naoya Tsurushita
Yun J Tso
Maximiliano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/822,300 external-priority patent/US7361740B2/en
Priority claimed from PCT/US2004/011213 external-priority patent/WO2004092219A2/en
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of WO2005123780A2 publication Critical patent/WO2005123780A2/en
Anticipated expiration legal-status Critical
Publication of WO2005123780A3 publication Critical patent/WO2005123780A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
PCT/US2005/011996 2004-04-09 2005-04-08 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis Ceased WO2005123780A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/822,300 2004-04-09
US10/822,300 US7361740B2 (en) 2002-10-15 2004-04-09 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
USPCT/US2004/011213 2004-04-09
PCT/US2004/011213 WO2004092219A2 (en) 2003-04-10 2004-04-09 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis

Publications (2)

Publication Number Publication Date
WO2005123780A2 WO2005123780A2 (en) 2005-12-29
WO2005123780A3 true WO2005123780A3 (en) 2007-11-15

Family

ID=35510325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011996 Ceased WO2005123780A2 (en) 2004-04-09 2005-04-08 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis

Country Status (1)

Country Link
WO (1) WO2005123780A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732570B2 (en) 2002-10-15 2010-06-08 Facet Biotech Corporation Alteration of Fc-fusion protein serum half-lives by mutagenesis
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12703738B2 (en) 2009-03-19 2026-08-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP4860703B2 (en) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド Optimized anti-CD30 antibody
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. CD19 OPTIMIZED ANTIBODY
EP2064240A2 (en) 2006-09-18 2009-06-03 Xencor, Inc. Optimized antibodies that target hm1.24
ES2687808T3 (en) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Constant region of modified antibody
KR101616758B1 (en) 2007-12-26 2016-04-29 젠코어 인코포레이티드 Fc VARIANTS WITH ALTERED BINDING TO FcRn
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
TW201920257A (en) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
CN102341411A (en) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 Anti-lymphotoxin antibodies
RU2595379C2 (en) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. ANTIBODIES AGAINST TNF-α AND USE THEREOF
RU2567639C2 (en) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Anti-vegf antibodies and applications thereof
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
HUE041426T2 (en) 2009-11-02 2019-05-28 Univ Washington Therapeutic nuclease preparations and methods
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
JP5551793B2 (en) 2010-04-01 2014-07-16 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー TRAIL sensitivity-enhancing composition containing an inhibitor for suppressing the expression or activity of TIP41, a TRAIL sensitizer target gene
PT2591006T (en) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processable single chain molecules and polypeptides made using same
TWI654203B (en) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha Antibodies with calcium-dependent antigen binding ability
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
CA2834626A1 (en) 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance
KR20250078601A (en) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting elimination of antigens
KR20210074395A (en) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 Drug containing carrier into cell for forming immune complex
CN107353342B (en) 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF receptor beta binding polypeptides
HRP20191920T1 (en) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
CN111548418A (en) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 Factor VIII compositions and methods of making and using same
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
WO2013148296A1 (en) 2012-03-28 2013-10-03 Sanofi Antibodies to bradykinin b1 receptor ligands
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
WO2013169657A1 (en) 2012-05-07 2013-11-14 Sanofi Methods for preventing biofilm formation
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
ES2770501T3 (en) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Factor VIII complex with XTEN and Von Willebrand factor protein and its uses
TWI855488B (en) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
FI3366705T3 (en) 2012-09-12 2023-07-28 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2648141C2 (en) 2012-09-19 2018-03-22 Эббви Биотерапьютикс Инк. Methods for identifying antibodies with reduced immunogenicity
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
RS61387B2 (en) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Optimized factor viii gene
US9580511B2 (en) 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
EP2970489A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
ES2699599T3 (en) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Fc variants
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
BR112016002753A2 (en) 2013-08-13 2017-11-21 Sanofi Sa antibodies to plasminogen activator inhibitor-1 (parent-1) and uses thereof
TW201722994A (en) 2013-08-13 2017-07-01 賽諾菲公司 Antibody to plasminogen activin inhibitor-1 (PAI-1) and use thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
SI3063275T1 (en) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EA201691111A1 (en) 2014-01-10 2017-01-30 Байоджен Ма Инк. CHEMERAL PROTEINS OF FACTOR VIII AND THEIR APPLICATION
HUE061339T2 (en) 2014-03-19 2023-06-28 Genzyme Corp Site-specific glycoengineering of targeting moieties
CA2943242A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN107001440A (en) 2014-09-26 2017-08-01 拜耳制药股份公司 Stabilized adrenomedulin derivative and application thereof
PL3204425T3 (en) 2014-10-09 2021-03-08 Genzyme Corporation Glycoengineered antibody drug conjugates
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
MX2017005774A (en) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
CN114773469B (en) 2015-02-05 2025-12-19 中外制药株式会社 Antibodies comprising ion concentration-dependent antigen binding domains, variants of the FC region, IL-8-binding antibodies and uses thereof
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CN108026172B (en) 2015-06-26 2022-04-29 赛诺菲生物技术公司 Monoclonal anti-IL-1RCP antibody
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
UA126016C2 (en) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Factor ix fusion proteins and methods of making and using same
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
EP3383909B1 (en) 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
JP2019501124A (en) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド Anti-huLRRC15 antibody drug conjugate and method of use thereof
EA201891420A1 (en) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
KR20180118659A (en) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. Optimized Factor VIII Factor
RS61659B1 (en) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Anti-cmet antibody drug conjugates and methods for their use
KR20190014525A (en) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. A bispecific binding protein that binds immuno-regulatory proteins to tumor antigens
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
SMT202100721T1 (en) 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
TWI760396B (en) 2016-06-17 2022-04-11 日商中外製藥股份有限公司 Anti-myostatin antibodies and methods of use
MA45554A (en) 2016-07-01 2019-05-08 Resolve Therapeutics Llc OPTIMIZED BINUCLEASE FUSIONS.
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Composition for preventing or treating IL-8 related diseases
MX2019002946A (en) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anti-pd-1(cd279) antibodies.
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
KR20190090827A (en) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. How Chimeric Coagulation Factors Can Be Used to Treat Hemophilic Arthrosis
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
UY37523A (en) 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc ANTI-OX40 ANTIBODIES AND ITS USES
ES3055314T3 (en) 2017-01-06 2026-02-11 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
TW201836647A (en) 2017-04-06 2018-10-16 美商艾伯維有限公司 Anti-prlr antibody-drug conjugates (adc) and uses thereof
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018209115A1 (en) 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
MX2020001593A (en) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc NUCLEIC ACID MOLECULES AND USES THEREOF.
CN111315767B (en) 2017-08-22 2025-03-18 萨纳生物有限责任公司 Soluble interferon receptor and its use
JP2021503885A (en) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
CN111699004A (en) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 Treatment of ophthalmic disorders
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CN112020516B (en) 2018-03-13 2025-01-03 塔斯克疗法有限公司 Anti-CD25 for tumor-specific cell depletion
TWI827585B (en) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
PE20210313A1 (en) 2018-03-28 2021-02-12 Bristol Myers Squibb Co INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
KR102914074B1 (en) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. Treatment of hemophilia A
CN112867394B9 (en) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 Anti-VLA-4 antibodies with reduced effector function
KR20210027426A (en) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 FGF21 formulation
JP7602454B2 (en) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic Acid Molecules and Their Use for Non-Viral Gene Therapy - Patent application
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
CN119033684A (en) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 Antibody formulations
BR112021008549A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
CA3124352A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
SG11202109331QA (en) 2019-03-01 2021-09-29 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
JP7575401B2 (en) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション Anti-alpha beta TCR binding polypeptides with reduced fragmentation - Patents.com
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
JP7803014B2 (en) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド Lentiviral vector formulations
BR112022012010A2 (en) 2019-12-18 2022-08-30 Hoffmann La Roche ANTIBODIES, ISOLATED NUCLEIC ACID, HOST CELL, PHARMACEUTICAL FORMULATION, USE OF THE ANTIBODY, METHOD OF PRODUCTION OF AN ANTIBODY, METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS CANCER, AND METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS AN INFLAMMATORY OR AUTOIMMUNE DISEASE
CN115052663B (en) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 ALK5 inhibitor conjugates and uses thereof
WO2021158938A1 (en) 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Il-10 and uses thereof
AU2021225962A1 (en) 2020-02-28 2022-10-20 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
JP7859981B2 (en) 2020-03-06 2026-05-15 ジーオー セラピューティクス，インコーポレイテッド Antiglyco-CD44 antibody and its use
JP2023537565A (en) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド Methods for removing free factor VIII from preparations of lentiviral vectors modified to express proteins
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc Compositions for increasing the half-life of a therapeutic agent in farm animals and methods of use
JP2024501452A (en) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer patients with tumor-infiltrating lymphocyte therapy in combination with BRAF inhibitors and/or MEK inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
JP2023554395A (en) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors
JP2024501845A (en) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド Devices and processes for automated production of tumor-infiltrating lymphocytes
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
JP2024509184A (en) 2021-03-05 2024-02-29 アイオバンス バイオセラピューティクス，インコーポレイテッド Tumor preservation and cell culture composition
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
TW202304480A (en) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CN118019546A (en) 2021-03-23 2024-05-10 艾欧凡斯生物治疗公司 CISH gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy
EP4314253A2 (en) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2024523034A (en) 2021-06-18 2024-06-25 エフ． ホフマン－ラ ロシュ アーゲー Bispecific anti-CCL2 antibodies
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
JP2024531915A (en) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド Anti-glyco-MUC antibodies and uses thereof
JP2024534910A (en) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド Anti-glycolic LAMP1 antibodies and uses thereof
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
JP2025503987A (en) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド Tumor-infiltrating lymphocytes engineered to express a payload
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
JP2025512313A (en) 2022-04-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
JP2026513101A (en) 2022-10-25 2026-04-23 アブリンクス エン．ヴェー． Enhanced effector function of glycosylated Fc mutant polypeptide
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
US20260124242A1 (en) 2022-11-04 2026-05-07 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
US20260217861A1 (en) 2022-12-22 2026-07-30 Jjulius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
TW202448960A (en) 2023-02-07 2024-12-16 美商Ｇｏ治療公司 Antibody fusion proteins comprising anti-glyco-muc4 antibodies and mic protein α1-α2 domains, and their uses
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Lentiviral vectors encoding cytokines and their use for the production of tumor-infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
TW202525845A (en) 2023-08-23 2025-07-01 法商賽諾菲公司 Ctla-4-based lysosomal degraders and uses thereof
IL328125A (en) 2023-11-06 2026-06-01 Iovance Biotherapeutics Inc Treatment of endometrial cancer using tumor-infiltrating lymphocytes
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
WO2026072794A2 (en) 2024-09-26 2026-04-02 Iovance Biotherapeutics, Inc. Expansion processes for til product enriched with neoantigen- reactive t cells (narts)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197297B1 (en) * 1995-02-23 2001-03-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Monoclonal antibody specific to polypeptide which induces interferon-gamma production
US6388487B1 (en) * 1999-06-04 2002-05-14 Mitsubishi Denki Kabushiki Kaisha Schmitt circuit
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197297B1 (en) * 1995-02-23 2001-03-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Monoclonal antibody specific to polypeptide which induces interferon-gamma production
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6388487B1 (en) * 1999-06-04 2002-05-14 Mitsubishi Denki Kabushiki Kaisha Schmitt circuit
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US7732570B2 (en) 2002-10-15 2010-06-08 Facet Biotech Corporation Alteration of Fc-fusion protein serum half-lives by mutagenesis
US8624007B2 (en) 2002-10-15 2014-01-07 Abbvie Biotherapeutics Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12703738B2 (en) 2009-03-19 2026-08-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

Also Published As

Publication number Publication date
WO2005123780A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2004092219A3 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004035752A3 (en) ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2008022152A3 (en) Optimized antibodies that target cd19
EP2270045B8 (en) Antibodies against Clostridium difficile toxins and uses thereof
IL222756A0 (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
UA89017C2 (en) HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B
UA86605C2 (en) Antibody comprising a variant fc region
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2003074679A3 (en) Antibody optimization
NZ607711A (en) Antibodies directed to her-3 and uses thereof
WO2007143168A3 (en) High affinity antibodies to human il-6 receptor
WO2003048730A3 (en) Identification of high affinity molecules by limited dilution screening
MA34527B1 (en) ANTIBODIES AGAINST METALLOPROTEINASE OF MATRIX 9
WO2006014498A3 (en) Universal antibody libraries
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
WO2005065015A3 (en) Neutralizing antibodies and methods of use thereof
WO2007144619A3 (en) Antibodies selectively binding aggregated prion protein 106-126 and uses thereof
WO2007001895A3 (en) Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase
WO2006033742A3 (en) Engineered antibody fragment that irreversibly binds an antigen
WO2007034210A8 (en) Deglycosylated anti-muc-1 antibodies and uses thereof
WO2005000896A3 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
WO2007002525A3 (en) Tomoregulin antibodies and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase